Abstract:17099 Background: Prolonged infusion of gemcitabine have shown increased levels of the active triphosphate metabolite that theorically could increase the response rate and toxicity. The objectives of this study were to evaluated the efficacy and safety of this combination of using gemcitabine as a rate infusion of 10 mg/m2 per min with carboplatin in front-line chemonaive patients with advanced NSCLC. Methods: Fifty-four chemonaive patients have been included. 44 were male and 10 female. Median age was 63 years (19–75). 13% had ECOG 0 and 53.7% ECOG 1 and 33.3% ECOG 2. 32 (59.2%) patients had adenocarcinoma, 13 (24.1%) squamous cell, 1 (1.9%) large cell carcinoma, and 8 (14.8%) others. Eight (14.8%) had stage IIIB and 46 (85.2%) stage IV. Treatment was consisted of 1200 mg/m2 gemcitabine given as a 2-hour continuous infusion (10 mg/m2 per min) on days 1 and 8 of each cycle an AUC 5 carboplatin as on day 1, repeating each cycle every 21 days. A total of 223 chemotherapy cycles were administered, with a median of 4 cycles per patient (range 1–6), and 15 (27.8%) patients received all six cycles. Results: Of the fifty-four patients enrolled, all were evaluated for toxicity (according to the WHO scale) and 51 assessed for response (according to the RECIST criteria), the overall response rate (ORR) was 41.2% (95% confidence interval, 28% to 57%), including two complete responses (CRs: 3.9%) and 19 partial responses (PRs: 37.3%). As per the intent-to-treat (ITT) analysis, the ORR was 38.9%. With a median follow-up time of 10.8 months, the median TTP was 5.0 months (range 3.7–6.3 months), median OS time was 11.5 months (range 9.9–13.1 months) and 1-year survival was 41.7% (95% CI 26% to 57%) and 2-year survival was 19.3% (4.4% to 34.2%).The main grade 3–4 toxicity consisted of neutropenia (55.6%) and thrombocytopenia (57.4%).Patients were required platelet transfusion in 27 cycles (12.1%) and haematopoietic growth factors support care in 56 (25.1%) cycles. No bleeding episodes were recorded. Grade 3 nausea/vomiting occurred in 5.6% and grade 1–2 skin rash occurred in 42.6%. Conclusions: Prolonged gemcitabine infusion combined with carboplatin is manageable tolerated and its efficacy is similar to that of other chemotherapeutic schemes used for NSCLC treatment. No significant financial relationships to disclose.

Three dimensional-conformal radiotherapy combined with gemcitabine chemotherapy for locally advanced non-small cell lung cancer

Three-dimensional Conformal Radiotherapy in Combination with Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.

Three Dimensional-conformal Radiotherapy Combined Concurrent Chemotherapy with Vinorelbine and Cisplatin for Stage Ⅲ Non-small Cell Lung Cancer

Three Dimensional-Conformal Radiotherapy Combined with Gemcitabine Chemotherapy for Locally Advanced Pancreatic Cancers

Three-dimensional Conformal Radiotherapy Combined with FOLFOX4 Chemotherapy for Unresectable Recurrent Rectal Cancer

Paclitaxel Combined with Three Dimensional-conformal Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

Clinical Study on the Effect of Hypofractionated Three -Dimensional Conformal Radiation Therapy in the Treatment of Non -Small Cell Lung Cancer

Three-dimensional Conformal Radiotherapy(3-Dcrt)combined with Radiofrequency Hyperthermia for Locally Advanced Non-Small-cell Lung Cancer(lansclc)

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Three Dimensional-Conformal Radiotherapy Combined with Capecitabine Chemotherapy for Locally Advanced Rectal Cancer

A prospective, multicenter, phase II clinical study of three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small-cell lung cancer-PPRA-RTOG003

3-Dimensional conformal radiotherapy and paclitaxel radiosensitization combined with chemotherapy on locally advanced non-small cell lung cancer

Clinical Study of Late-Course Three-Dimensional Conformal Radiotherapy for Esophageal Carcinoma

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

Prognosis of Three Dimensional Conformal Radiotherapy of Locally Advanced Non-small Cell Lung Cancer with Involved-field

An Analysis of Local Advanced Non-small Cell Lung Cancer Treated with Image-guided Hypofractionated Intensity Modulated Radiotherapy combined with Chemotherapy

Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small-cell Lung Cancer.

Comparisons of two chemoradiotherapy regimens for locally advanced non-squamous and non-small cell lung cancer

Phase II Trial of a 2-Hour Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

Radiotherapy Combined with Gefitinib for Patients with Locally Advanced Non-Small Cell Lung Cancer Who Are Unfit for Surgery or Concurrent Chemoradiotherapy: a Phase II Clinical Trial

A Phase II Trial of Accelerated Hypofractionated Three-Dimensional Conformal Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer